LLY vs NVO
Eli Lilly and Company vs Novo Nordisk A/S · Updated Mar 28, 2026
LLY — 4 winsNVO — 6 wins
Price Performance
LLY +6.78%NVO -47.99%
Performance
| LLY | NVO | |
|---|---|---|
| 1 Month | -14.15% | -4.49% |
| 3 Months | -18.53% | -31.64% |
| 6 Months | +22.78% | -35.89% |
| YTD | -18.36% | -29.38% |
| 1 Year | +6.12% | -49.91% |
| 3 Year | +152.20% | -36.65% |
| 5 Year | +449.95% | +9.08% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | -18.7% | +37.4% | +30.4% | +59.7% | +35.1% | +66.9% | +27.7% | +14.4% | +36.7% | +13.2% | -11.3% | +20.3% |
| NVO | -31.2% | -41.9% | -15.8% | +51.1% | +24.4% | +56.0% | +19.7% | +23.7% | -14.9% | +49.4% | -37.4% | +36.7% |
Valuation
| LLY | NVO | |
|---|---|---|
| P/E Ratio | 38.23 | — |
| Forward P/E | 26.69 | 1.79 |
| PEG Ratio | 1.85 | 4.35 |
| P/S Ratio | 13.14 | — |
| P/B Ratio | 32.28 | — |
| EV/EBITDA | 31.93 | — |
Financials
| LLY | NVO | |
|---|---|---|
| EPS (TTM) | $22.95 | — |
| Gross Margin | +82.52% | — |
| Operating Margin | +42.85% | — |
| Net Margin | +34.41% | — |
| ROE | +77.78% | — |
| ROA | +18.35% | — |
| Debt/Equity | 1.60 | — |
Growth
| LLY | NVO | |
|---|---|---|
| Revenue Growth YoY | +42.56% | — |
| Revenue Growth QoQ | +9.61% | — |
| EPS Growth YoY | +51.43% | — |
| EPS Growth QoQ | +19.00% | — |
Technical
| LLY | NVO | |
|---|---|---|
| RSI (14) | 26.41 | 21.67 |
| % From 20-Day SMA | -8.31% | -4.74% |
| % From 50-Day SMA | -12.88% | -22.00% |
| % From 200-Day SMA | -2.04% | -33.40% |
| % From 52-Week High | -22.63% | -55.88% |
| % From 52-Week Low | +40.66% | +0.22% |
Analyst Ratings
LLY
Buy(25 analysts)
Strong SellHoldStrong Buy
Price Target
$1243.95
+37.96% upside
NVO
—(0 analysts)
Strong SellHoldStrong Buy
Price Target
—
Overview
| LLY | NVO | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $856.56B | $176.82B |
| Shares Outstanding | 943.4M | — |
| Avg Volume (10D) | 3.02M | 17.84M |
| Dividend Yield | 0.69% | 3.09% |
Frequently Asked Questions
Is LLY or NVO a better buy right now?
Based on 10 comparable metrics, NVO leads in 6 categories while LLY leads in 4. NVO has a consensus analyst rating with 0 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, LLY or NVO?
Over the past year, LLY returned +6.12% compared to NVO's -49.91%. In the short term (1 month), LLY returned -14.15% vs NVO's -4.49%.
Is LLY or NVO more expensive?
LLY trades at a P/E of 38.23 compared to NVO's —. On a price-to-sales basis, LLY trades at 13.14x vs NVO's —x. Forward P/E: LLY at 26.69 vs NVO at 1.79.
Which stock has higher growth, LLY or NVO?
LLY's revenue grew +42.56% year-over-year compared to NVO's —. EPS growth: LLY at +51.43% vs NVO at —.
Do LLY and NVO pay dividends?
LLY pays a dividend with a yield of 0.69%. NVO pays a dividend with a yield of 3.09%.
Which stock do analysts prefer, LLY or NVO?
LLY has 25 analysts with a target price of $1243.95 (+37.96% upside). NVO has 0 analysts with a target of — (— upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.